Itraconazole, a new triazole that is orally active in aspergillosis
Open Access
- 1 October 1984
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 26 (4) , 527-534
- https://doi.org/10.1128/aac.26.4.527
Abstract
Itraconazole is a new orally active triazole derivative with broad-spectrum antifungal activity. This drug is effective in experimental aspergillosis and possesses in vitro activity against various species and strains of Aspergillus. Morphological destruction of inoculated hyphae and complete inhibition of hyphal outgrowth in culture is obtained from 0.07 micrograms ml-1 (10(-7)M) onward. These properties make itraconazole a likely candidate for clinical evaluation in disseminated aspergillosis.Keywords
This publication has 9 references indexed in Scilit:
- An Ultrastructural and Cytochemical Study of Candida aIbicans after in Vitro Treatment with ImidazolesMycoses, 2009
- Antimycotic azoles. 7. Synthesis and antifungal properties of a series of novel triazol-3-onesJournal of Medicinal Chemistry, 1984
- [Chemotherapy of aspergillus lung disease].1983
- The antifungal activity of ketoconazoleThe American Journal of Medicine, 1983
- The mechanism of action of the new antimycotic ketoconazoleThe American Journal of Medicine, 1983
- The activity of ketoconazole in clinical isolates of candida albicans cultured in a mycelium promoting medium.1981
- Invasive Aspergillosis in Acute Leukemia: Correlation with Nose Cultures and Antibiotic UseAnnals of Internal Medicine, 1979
- Aspergillus pneumonia in hematologic malignancy. Improvements in diagnosis and therapyArchives of internal medicine (1960), 1977
- Miconazole, a Broad-Spectrum Antimycotic Agent with Antibacterial ActivityChemotherapy, 1972